Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 19.875p 19.75p 20.25p - - - 86 08:00:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 104.58

Vernalis (VER) Latest News (1)

More Vernalis News
Vernalis Takeover Rumours

Vernalis (VER) Share Charts

1 Year Vernalis Chart

1 Year Vernalis Chart

1 Month Vernalis Chart

1 Month Vernalis Chart

Intraday Vernalis Chart

Intraday Vernalis Chart

Vernalis (VER) Discussions and Chat

Vernalis Forums and Chat

Date Time Title Posts
26/4/201723:44VERNALIS - time to buy?1,589.00
24/10/201019:57VERNALIS - 500p by December 2010?465.00
15/9/200917:32Vernalis (VER): Charts and discussion thread38.00
15/9/200917:31VERNALIS *** UNDERVALUED***1.00
15/9/200916:38Vernalis - short this junk to 40p?23.00

Add a New Thread

Vernalis (VER) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-04-27 15:38:1020.005,0001,000.00O
2017-04-27 13:18:3319.883,743743.92O
2017-04-27 13:06:5419.837,8121,548.73O
2017-04-27 12:58:5119.893,016599.88O
View all Vernalis trades in real-time

Vernalis (VER) Top Chat Posts

Vernalis Daily Update: Vernalis is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VER. The last closing price for Vernalis was 19.88p.
Vernalis has a 4 week average price of 19.75p and a 12 week average price of 19.75p.
The 1 year high share price is 50.50p while the 1 year low share price is currently 19.75p.
There are currently 526,196,204 shares in issue and the average daily traded volume is 1,197,340 shares. The market capitalisation of Vernalis is £104,581,495.55.
cumnor: Not a pharmacokinetic or formulation issue? Did they mention labeling? If it was something simple then why not say so. Was it a safety issue? Why not say if it was or was not? Investors have the right to be kept fully informed. The FDA are serious people-don't issue complete response letters wily-nily. Are other products with similar profiles going to be similarly challenged? Can cost millions and take years to challenge the FDA or get them round to your way of thinking. RNS too vague to be sure this is not finished imo, and if Tuzistra sales don't start taking off Ver could be in in deep trouble imo. Also lack of news on Moxtag a concern imo for investors. Having started with huge cash pile this could easily be frittered away given costs of running an expensive mgmt team, sales force, regulatory hurdles etc. Without serious good news on sales, deals, approvals etc today's share price could look expensive before the year is out. imo
romeike: Unfortunately thin news flow until June may not provide the necessary interest needed to improve the share price beyond pre-update levels but there is the possibility of early resolution to the moxatag supply issue and further research milestones. Most other news expected H2.
romeike: I doubt there is more to fall, I expect the share price to gradually recover to same level as before the results, about 32p. The results raised more questions that answers as is so common on AIM but the company is in a decent financial position and has everything to play for still.
woodcutter: 11586 prescriptions in six months seems pretty insignificant to me given the size of the market, share price reaction tells the story imv. may see it drop further yet aimho woody
bountyhunter: interims announced... Ian Garland, Chief Executive Officer, commented, "We are encouraged with the progress we have made in the last six months as we continued to expand our sales and saw further progress in our cough cold development pipeline. "Midway through the 2016/17 cough cold season we have seen Tuzistra(R) XR prescriptions continue to grow steadily. We believe the emergence of high performing sales representatives in all regions across the US validates the market potential for Tuzistra(R) XR. We are, however, still in the early stages of the launch and our focus for the second half of the season is to drive sales-force effectiveness and so further increase the proportion of high performing sales territories. With continued prescription growth expected, the annualised run-rate at the end of June 2017 should provide a more meaningful predictor of sales performance for future years. "We expect to achieve a number of milestones from the remainder of the cough cold franchise in 2017, including potential approvals by FDA of CCP-07 and CCP-08. We also continue to seek other opportunities to leverage our US commercial infrastructure and remain very excited about the growth potential of the business." Presentation & Conference Call Vernalis management will host a presentation at 9.30am (UK) today at the offices of FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. It will also be available via webcast at hxxp:// and and via conference call, which can be joined by dialling: +44 (0) 20 3003 2666, Passcode 5780976# Please contact Jack Bower at FTI consulting +44 (0) 20 3727 1000 for details. Http://
romeike: Good results tomorrow ought to trigger a decent recovery in the share price here. I think we are looking for some evidence that that Tuzistra XR will at the very least comfortably replace revenue that would previously have come from sales of Frovatriptan. Yes, for the current year the recently announced milestone payment already more than achieves this, but Tuzistra XR will be a reliable, regular source of income that keeps growing over the long term. I'm looking forward to any further information about the H2 launches that will fully utilise the sales team into which so much investment went last year. Good luck all!
woodcutter: I've been researching a number of pharma co's where the share price has fallen considerably recently and once again I'm finding a similar pattern on director emoluments. For a business that turned over roughly £12m last year to see the directors taking out £1.7m in remuneration seems unacceptable to me. Noses in the trough comes to mind. Garland was paid £865K of which £363K was bonus related. All the bonus payments were attributed to company product milestones nothing was realted to anything financial neither was it related to share price performance. There's a total of 8 directors including the non execs for a business with £12m revenue. Woodford and Invesco need to pressure the board to show restraint. I've no doubt there's potential here but it needs to be realised before these kind of awards are given. One question that does seem obvious is what differentiates VER cold medication from the wider range of products already on the market? (I know they do more than cold remedies but these seem to be at the forefront of immediate revenue generation) It's now on my watch list but need to see greater revenue and stricter cost control otherwise there'll end up being a further placing. I await the results with anticipation. woody
bountyhunter: RNS today... "Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc Vernalis plc is pleased to announce the achievement of a clinical milestone from its collaboration with Corvus Pharmaceuticals Inc ("Corvus") triggering a payment of $3 million to Vernalis. In February 2015, the Company licensed exclusive, worldwide rights to its adenosine receptor antagonist programme, CPI-444, for use in all therapeutic applications to Corvus, a US-based biotechnology company focused on developing novel immuno-oncology therapies. CPI-444 is a patented small molecule that is now being evaluated in a Phase 1/1b trial in patients with advanced cancers. It is the lead molecule in Corvus' pipeline and is being developed both as a single agent and in combination therapy. The clinical trial utilizes an adaptive design that allows expansion of disease-specific cohorts upon reaching certain pre-defined endpoints. Corvus announced positive data from its Phase 1/1b study in January 2017, having achieved the clinical study protocol criteria for expansion in the cohort of patients with renal cell carcinoma with single agent CPI-444. This study expansion triggers the first clinical milestone payment of $3 million under the licensing agreement. Corvus has stated that, if early findings are confirmed with longer follow up and a larger set of patients in this expanded study, a registration trial could commence by the end of 2017. Corvus was launched through a $33.3 million Series A fundraising in 2014 by the founder and former senior management at Pharmacyclics Inc and it raised a further $74.8 million Series B fundraising in 2015 and $70.7 million via a US IPO in March 2016. The licensing deal has the potential for Vernalis to earn approximately $220 million in milestones from all indications, subject to development, regulatory and sales milestones being achieved. In addition, there are mid-single digit royalties payable if a product reaches the market, with the potential to reach low-double digit royalties in certain circumstances..." Http://
bountyhunter: How do you work that out from the following statements in today's RNS? -- "Focused US primary care sales force fully recruited, trained and deployed to the field -- US rights to Moxatag(R) , the only US approved once-a-day formulation of amoxicillin, acquired in October 2015, validating the Company's ability to expand its US commercial portfolio ...Re-launch Moxatag(R) in the US market through our focused US primary care sales force (H2 2016 calendar year) ...We will leverage this investment and our US commercial infrastructure to launch the once-a-day antibiotic, Moxatag(R) in the second half of 2016. ...Our cash position was bolstered following the recent equity raise to continue the promotional investment in Tuzistra(R) XR as well as launch Moxatag(R) and our additional products, CCP-07 and CCP-08 in the near term. We remain very excited about the growth potential of the business." There is still just over 3 months to go to the end of the H2 2016 calendar year with autumn/winter just starting.
twodegrees: fhmktg, this was recovering very well in fact had hit new highs and has been walked all the way back down because of possible supply issues. I am annoyed that the company has not given any indication yet if the supply chain has been sorted and that has contributed to a share price fall of over 505 in 4 I tend to disagree that progress is being made. I f we have a product and cannot get it to market...then ????????
Vernalis share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170428 08:27:47